American Lung Association Warns of 2026 Federal Tobacco Policy Shifts Impacting Prevention

• The CDC posted its first large set of genetic data from 1,000 measles viruses circulating in the US last year, with more data expected soon to assess if elimination status has been lost. • In 2025, measles cases reached 2,285 across 44 states—the worst in over 30 years—while 2026 has seen 1,575 cases by late March amid declining vaccination rates. • Delays in data release stemmed from mass layoffs and resignations; researchers criticize the Trump administration's budget cuts and slow outbreak response.

• Pfizer and BioNTech stopped a large US trial of their updated COVID-19 vaccine targeting healthy adults aged 50-64 due to inability to recruit 25,000-30,000 participants without conditions like hypertension or diabetes. • The halt highlights recruitment challenges amid low interest in trials for healthy populations. • This occurs against a backdrop of shifting vaccine policies under the Trump administration, prioritizing chronic disease over broad COVID efforts.

• The CDC temporarily halted testing for rabies and pox viruses—including those for smallpox and mpox—to assist state labs, as part of an agency-wide review started in late 2024. • By July, the rabies team will have only one advisor left for states, while the pox virus team will have none due to dwindling staff from resignations and layoffs. • Experts express concern over reduced clinical expertise, potentially weakening national responses to outbreaks.

• US poison centers reported a sharp increase in kratom-containing kava exposures from 2000-2025, serving as an early warning for substance harms. • After a 2002 FDA advisory on liver injury, kava reports declined but rose substantially since 2011, now mostly involving men aged 20+ with serious outcomes and co-use with kratom. • Higher rates of severe medical effects underscore risks of increasing popularity and polysubstance use.

• Eight defendants, including three nurses, a chiropractor, and a psychologist, have been arrested on federal charges for defrauding the health care system of more than $50 million through sham hospice care facilities. • The scheme involved running hospice operations that billed Medicare by enrolling people without terminal illnesses as beneficiaries, with Valley Pacific Hospice Inc. in Simi Valley having its Medicare enrollment revoked in August 2024. • The arrests were coordinated with the Vice President's Task Force to Eliminate Fraud, with six defendants making initial appearances in U.S. District Court in Los Angeles and one in Idaho.

• Florida reported 143 measles cases as of March 21, 2026, with 73% concentrated in Collier County, marking a decline from 139 cases the previous week. • The state has dropped to the fourth-highest number of measles cases nationally as the spread slows, indicating a shift in outbreak trajectory. • The majority of cases remain geographically concentrated, with nearly three-quarters of infections occurring in a single county, suggesting localized transmission patterns.

• FDA announced on April 1, 2026, that new drug approvals last year reached near-record levels, surpassing five-, ten-, and multi-year averages. • This update highlights continued acceleration in innovative therapies reaching US patients, boosting treatment options for various diseases. • Strong approval momentum underscores FDA's commitment to expediting safe, effective drugs amid public health priorities like cancer and rare diseases.

• Express Scripts added CARDAMYST (etripamil) nasal spray to its commercial national formularies effective March 27, 2026, expanding access for commercially insured patients. • The FDA-approved self-administered spray converts acute paroxysmal supraventricular tachycardia (PSVT) episodes to sinus rhythm in adults. • This coverage decision makes the first-in-class treatment broadly affordable across the U.S., improving cardiovascular care options.

• Soligenix's HyBryte for cutaneous T-cell lymphoma (CTCL) has a second Phase 3 trial underway with enrollment of approximately 80 subjects, interim analysis in Q2 2026, and top-line results in H2 2026. • Previous Phase 3 trials showed statistical significance in primary endpoints across multiple cycles, following FDA NDA submission and RTF letter. • The program targets unmet needs in rare dermatological cancers with ongoing FDA discussions for development path.

• Bluestem Health in Lincoln, Nebraska, serving 21,000 low-income and uninsured patients, has operated at a loss for two years and anticipates worsening conditions due to new Medicaid work rules under President Trump's One Big Beautiful Bill Act. • Nebraska becomes the first state to enforce work requirements for certain Medicaid enrollees, risking coverage loss and threatening clinic viability, as stated by CEO Brad Meyer. • The policy darkens the outlook for government-backed clinics nationwide by reducing patient access to care amid rising operational costs.

• Congress reauthorized the Dr. Lorna Breen Health Care Provider Protection Act, extending mental health support programs for healthcare professionals through September 2030. • Named after emergency physician Dr. Lorna Breen, who died by suicide during the COVID-19 pandemic, the law addresses burnout among nurses and others. • The legislation continues federal initiatives to improve workplace conditions and reduce mental health challenges in healthcare.

• US healthcare costs for employers are forecasted to increase more than 9% in 2026, driven by regulatory changes, labor shortages, and rising demand. • Growing use of specialty drugs, particularly GLP-1 medications for weight loss and diabetes, significantly contributes to the cost surge. • Businesses face pressure to redesign benefits packages amid these economic pressures on public health spending.